CG Oncology (CGON) Accumulated Expenses (2023 - 2026)

CG Oncology has reported Accumulated Expenses for 4 years, with the latest figure at $25.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 65.52% year-over-year to $25.9 million; the trailing twelve-month figure through Mar 2026 stood at $25.9 million (up 65.52% YoY), and the FY2025 full-year result was $24.2 million, up 65.07% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $25.9 million, up from $24.2 million in the prior quarter.
• The five-year high for Accumulated Expenses was $25.9 million in Q1 2026, with the low at $5.1 million in Q1 2024.
• Historically, Accumulated Expenses has averaged $15.8 million across 4 years, with a median of $15.2 million in 2024.
• Annual changes were most pronounced in 2024 — Accumulated Expenses surged 40.43% — and 2025, when it jumped 222.36%.
• CG Oncology's Accumulated Expenses stood at $10.4 million in 2023, then surged by 40.43% to $14.7 million in 2024, then jumped by 65.07% to $24.2 million in 2025, then advanced by 7.05% to $25.9 million in 2026.
• The last three Accumulated Expenses figures came in at $25.9 million (Q1 2026), $24.2 million (Q4 2025), and $20.4 million (Q3 2025), per Business Quant data.